White House announces deals with Eli Lilly, Novo Nordisk to lower drug costs
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed nations, known as the most-favored-nation price. Like other recent agreements, Eli Lilly and Novo Nordisk will provide all state Medicaid programs access to MFN prices on their products and must offer medicines at deep discounts off the list price when selling directly to American consumers. In addition, Novo Nordisk committed to a $10 billion investment to expand its U.S. manufacturing capacity, while Eli Lilly announced it would provide at least $27 billion in new U.S. manufacturing investments.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Innovation Center yesterday announced the launch of a new model under Medicaid and the Children’s Health…
Headline
The Centers for Medicare & Medicaid Services March 11 issued guidance to state survey agency directors clarifying and reinforcing the roles and…
Headline
The Medicaid and CHIP Payment and Access Commission March 12 released its March 2026 report to Congress. The first chapter includes a recommendation to…
Headline
The Centers for Medicare & Medicaid Services March 6 issued guidance to states on transitioning to six-month Medicaid redeterminations in 2027, a change…
Headline
Republican leaders on the House Committee on Energy and Commerce March 5 announced they were expanding their ongoing investigation into waste, fraud and abuse…
Headline
The Centers for Medicare & Medicaid Services has released a toolkit that outlines strategies for states to strengthen access to behavioral health services…